Pfizer forced to release results from their Covid-19 vaccine, and the early results are horrific.

This document provides an integrated analysis of the cumulative post-authorization safety data, including U.S. and foreign post-authorization adverse event reports received through 28 February 2021.

The document reveals that within just 90 days after the EUA release of Pfizer’s mRNA vaccine, the company was already aware of voluntary adverse reaction reports that revealed 1,223 deaths and over 42,000 adverse reports describing a total of 158,893 adverse reactions. The reports originated from numerous countries, including the United States, United Kingdom, Italy, Germany, France, Portugal, Spain and other nations.

This image has an empty alt attribute; its file name is screenshot-2021-12-03-at-17-30-07-5-3-6-postmarketing-experience-1-pdf.png

Of special interest is what happens to pregnant and breastfeeding mothers

This is alarming, since a gestation period is 9 months, and these are snapshots the first 90 days after introducing the vaccine. The question that many women have, especially health care women that have seen what is going on is: How safe is this vaccine really? Will it cause infertility? Will it drastically increase stillbirth? Will it damage my child in the womb? We now have nearly a year of data, and no one comes out and assures us that none of these things are happening, just an increase in deaths, and a large number of adverse reactions.

The second set of questions are: How much worse is COVID-19 itself compared to the vaccine? Does COVID-19 cause infertility? Is blood clotting worse? It maybe that for children and young adults the vaccine is worse than COVID itself, other data seems to suggest so for people under 45 years of age.

This vaccine should be halted for people under age 45 until answers are given. There seems to be a benefit for older people, a substantially reduced death risk.

BNT162b2
5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports
CONFIDENTIAL
Page 1
APPENDIX 1. LIST OF ADVERSE EVENTS OF SPECIAL INTEREST
1p36 deletion syndrome; 2-Hydroxyglutaric aciduria; 5’nucleotidase increased;

Acoustic neuritis; Acquired C1 inhibitor deficiency;

Acquired epidermolysis bullosa; Acquired epileptic aphasia;

Acute cutaneous lupus erythematosus; Acute disseminated encephalomyelitis;

Acute encephalitis with refractory, repetitive partial seizures;

Acute febrile neutrophilic dermatosis; Acute flaccid myelitis;

Acute haemorrhagic leukoencephalitis; Acute haemorrhagic oedema of infancy;

Acute kidney injury; Acute macular outer retinopathy;

Acute motor axonal neuropathy; Acute motor-sensory axonal neuropathy;

Acute myocardial infarction; Acute respiratory distress syndrome;

Acute respiratory failure; Addison’s disease; Administration site thrombosis;

Administration site vasculitis; Adrenal thrombosis;

Ageusia;Agranulocytosis; Air embolism;

Alanine aminotransferase abnormal; Alanine aminotransferase increased;

Alcoholic seizure; Allergic bronchopulmonary mycosis;

Allergic oedema; Alloimmune hepatitis; Alopecia areata; Alpers disease;

Alveolar proteinosis; Ammonia abnormal; Ammonia increased;

Amniotic cavity infection; Amygdalohippocampectomy; Amyloid arthropathy;

Amyloidosis; Amyloidosis senile; Anaphylactic reaction; Anaphylactic shock;

Anaphylactic transfusion reaction; Anaphylactoid reaction; Anaphylactoid shock;

Anaphylactoid syndrome of pregnancy; Angioedema; Angiopathic neuropathy;

Ankylosing spondylitis; Anosmia; Antiacetylcholine receptor antibody positive;

Anti-actin antibody positive; Anti-aquaporin-4 antibody positive;

Anti-basal ganglia antibody positive;

Anti-cyclic citrullinated peptide antibody positive;

Anti-epithelial antibody positive; Anti-erythrocyte antibody positive;

Anti-exosome complex antibody positive; Anti-GAD antibody negative;

Anti-GAD antibody positive; Anti-ganglioside antibody positive;

Antigliadin antibody positive;

Anti-glomerular basement membrane disease;

Anti-glycyl-tRNA synthetase antibody positive;

Anti-HLA antibody test positive; Anti-IA2 antibody positive;

Anti-insulin antibody increased; Anti-insulin antibody positive;

Anti-insulin receptor antibody increased; Anti-insulin receptor antibody positive;

Anti-interferon antibody negative; Anti-interferon antibody positive;

Anti-islet cell antibody positive; Antimitochondrial antibody positive;

Anti-muscle specific kinase antibody positive;

Anti-myelin-associated glycoprotein antibodies positive;

Anti-myelin-associated glycoprotein associated polyneuropathy;

Antimyocardial antibody positive; Anti-neuronal antibody positive;

Antineutrophil cytoplasmic antibody increased;

Antineutrophil cytoplasmic antibody positive;

Anti-neutrophil cytoplasmic antibody positive vasculitis;

Anti-NMDA antibody positive; Antinuclear antibody increased;

Antinuclear antibody positive; Antiphospholipid antibodies positive;

Antiphospholipid syndrome; Anti-platelet antibody positive;

Anti-prothrombin antibody positive; Antiribosomal P antibody positive;

Anti-RNA polymerase III antibody positive;

Anti-saccharomyces cerevisiae antibody test positive;

Anti-sperm antibody positive; Anti-SRP antibody positive; Antisynthetase syndrome;

Anti-thyroid antibody positive; Anti-transglutaminase antibody increased;

Anti-VGCC antibody positive; Anti-VGKC antibody positive;

Anti-vimentin antibody positive; Antiviral prophylaxis; Antiviral treatment;

Anti-zinc transporter 8 antibody positive; Aortic embolus; Aortic thrombosis;

Aortitis; Aplasia pure red cell; Aplastic anaemia; Application site thrombosis;

Application site vasculitis; Arrhythmia;Arterial bypass occlusion;

Arterial bypass thrombosis; Arterial thrombosis; Arteriovenous fistula thrombosis;

Arteriovenous graft site stenosis; Arteriovenous graft thrombosis;

Arteritis; Arteritis coronary; Arthralgia; Arthritis; Arthritis enteropathic; Ascites;

Aseptic cavernous sinus thrombosis; Aspartate aminotransferase abnormal;

Aspartate aminotransferase increased; Aspartate-glutamate-transporter deficiency;

AST to platelet ratio index increased; AST/ALT ratio abnormal; Asthma;

Asymptomatic COVID-19; Ataxia; Atheroembolism; Atonic seizures;

Atrophic thyroiditis; Atypical benign partial epilepsy; Atypical pneumonia; Aura;

Autoantibody positive;Autoimmune anaemia; Autoimmune aplastic anaemia;

Autoimmune arthritis; Autoimmune blistering disease; Autoimmune cholangitis;

Autoimmune colitis; Autoimmune demyelinating disease; Autoimmune dermatitis;

Autoimmune disorder; Autoimmune encephalopathy;

Autoimmune endocrine disorder; Autoimmune enteropathy;

Autoimmune eye disorder; Autoimmune haemolytic anaemia;

Autoimmune heparin-induced thrombocytopenia; Autoimmune hepatitis;

Autoimmune hyperlipidaemia; Autoimmune hypothyroidism;

Autoimmune inner ear disease; Autoimmune lung disease;

Autoimmune lymphoproliferative syndrome; Autoimmune myocarditis;

Autoimmune myositis; Autoimmune nephritis; Autoimmune neuropathy;

Autoimmune neutropenia; Autoimmune pancreatitis; Autoimmune pancytopenia;

Autoimmune pericarditis; Autoimmune retinopathy; Autoimmune thyroid disorder;

Autoimmune thyroiditis; Autoimmune uveitis;

Autoinflammation with infantile enterocolitis;

Autoinflammatory disease; Automatism epileptic;

Autonomic nervous system imbalance; Autonomic seizure; Axial spondyloarthritis;

Axillary vein thrombosis; Axonal and demyelinating polyneuropathy;

Axonal neuropathy; Bacterascites; Baltic myoclonic epilepsy; Band sensation;

Basedow’s disease; Basilar artery thrombosis; Basophilopenia;B-cell aplasia;

Behcet’s syndrome; Benign ethnic neutropenia;

Benign familial neonatal convulsions;

Benign familial pemphigus; Benign rolandic epilepsy;

Beta-2 glycoprotein antibody positive; Bickerstaff’s encephalitis;

Bile output abnormal; Bile output decreased; Biliary ascites;

Bilirubin conjugated abnormal; Bilirubin conjugated increased;

Bilirubin urine present; Biopsy liver abnormal; Biotinidase deficiency;

Birdshot chorioretinopathy; Blood alkaline phosphatase abnormal;

Blood alkaline phosphatase increased; Blood bilirubin abnormal;

Blood bilirubin increased; Blood bilirubin unconjugated increased;

Blood cholinesterase abnormal; Blood cholinesterase decreased;

Blood pressure decreased; Blood pressure diastolic decreased;

Blood pressure systolic decreased; Blue toe syndrome;

Brachiocephalic vein thrombosis; Brain stem embolism; Brain stem thrombosis;

Bromosulphthalein test abnormal; Bronchial oedema;

Bronchitis; Bronchitis mycoplasmal; Bronchitis viral;

Bronchopulmonary aspergillosis allergic; Bronchospasm; Budd-Chiari syndrome;

Bulbar palsy; Butterfly rash; C1q nephropathy; Caesarean section;

Calcium embolism; Capillaritis; Caplan’s syndrome; Cardiac amyloidosis;

Cardiac arrest; Cardiac failure; Cardiac failure acute; Cardiac sarcoidosis;

Cardiac ventricular thrombosis; Cardiogenic shock; Cardiolipin antibody positive;

Cardiopulmonary failure; Cardio-respiratory arrest; Cardio-respiratory distress;

Cardiovascular insufficiency; Carotid arterial embolus; Carotid artery thrombosis;

Cataplexy;Catheter site thrombosis;

Catheter site vasculitis;

Cavernous sinus thrombosis;

CDKL5 deficiency disorder;

CEC syndrome;

Cement embolism;

Central nervous system lupus;

Central nervous system vasculitis;

Cerebellar artery thrombosis;

Cerebellar embolism;

Cerebral amyloid angiopathy;

Cerebral arteritis;

Cerebral artery embolism;

Cerebral artery thrombosis;

Cerebral gas embolism;

Cerebral microembolism;

Cerebral septic infarct;

Cerebral thrombosis;

Cerebral venous sinus thrombosis;

Cerebral venous thrombosis;

Cerebrospinal thrombotic tamponade;

Cerebrovascular accident;

Change in seizure presentation;

Chest discomfort;

Child-Pugh-Turcotte score abnormal;

Child-Pugh-Turcotte score increased;

Chillblains;

Choking;

Choking sensation;

Cholangitis sclerosing;

Chronic autoimmune glomerulonephritis;

Chronic cutaneous lupus erythematosus;

Chronic fatigue syndrome;

Chronic gastritis;

Chronic inflammatory demyelinating polyradiculoneuropathy;

Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids;

Chronic recurrent multifocal osteomyelitis;

Chronic respiratory failure;

Chronic spontaneous urticaria;

Circulatory collapse;

Circumoral oedema;

Circumoral swelling;

Clinically isolated syndrome;

Clonic convulsion;

Coeliac disease;

Cogan’s syndrome;

Cold agglutinins positive;

Cold type haemolytic anaemia;

Colitis;

Colitis erosive;

Colitis herpes;

Colitis microscopic;

Colitis ulcerative;

Collagen disorder;

Collagen-vascular disease;

Complement factor abnormal;

Complement factor C1 decreased;

Complement factor C2 decreased;

Complement factor C3 decreased;

Complement factor C4 decreased;

Complement factor decreased;

Computerised tomogram liver abnormal;

Concentric sclerosis;

Congenital anomaly;

Congenital bilateral perisylvian syndrome;

Congenital herpes simplex infection;

Congenital myasthenic syndrome;

Congenital varicella infection;

Congestive hepatopathy;

Convulsion in childhood;

Convulsions local;

Convulsive threshold lowered;

Coombs positive haemolytic anaemia;

Coronary artery disease;

Coronary artery embolism;

Coronary artery thrombosis;

Coronary bypass thrombosis;

Coronavirus infection;

Coronavirus test;

Coronavirus test negative;

Coronavirus test positive;

Corpus callosotomy;

Cough;

Cough variant asthma;

COVID-19;

COVID-19 immunisation;

COVID-19 pneumonia;

COVID-19 prophylaxis;

COVID-19 treatment;

Cranial nerve disorder;

Cranial nerve palsies multiple;

Cranial nerve paralysis;

CREST syndrome;

Crohn’s disease;

Cryofibrinogenaemia;

Cryoglobulinaemia;

CSF oligoclonal band present;

CSWS syndrome;

Cutaneous amyloidosis;

Cutaneous lupus erythematosus;

Cutaneous sarcoidosis;

Cutaneous vasculitis;

Cyanosis;

Cyclic neutropenia;

Cystitis interstitial;

Cytokine release syndrome;

Cytokine storm;

De novo purine synthesis inhibitors associated acute inflammatory syndrome;

Death neonatal;

Deep vein thrombosis;

Deep vein thrombosis postoperative;

Deficiency of bile secretion;

Deja vu;Demyelinating polyneuropathy;

Demyelination;

Dermatitis;

Dermatitis bullous;

Dermatitis herpetiformis;

Dermatomyositis;

Device embolisation;

Device related thrombosis;

Diabetes mellitus;

Diabetic ketoacidosis;

Diabetic mastopathy;

Dialysis amyloidosis;

Dialysis membrane reaction;

Diastolic hypotension;

Diffuse vasculitis;

Digital pitting scar;

Disseminated intravascular coagulation;

Disseminated intravascular coagulation in newborn;

Disseminated neonatal herpes simplex;

Disseminated varicella;

Disseminated varicella zoster vaccine virus infection;

Disseminated varicella zoster virus infection;

DNA antibody positive;Double cortex syndrome;

Double stranded DNA antibody positive;

Dreamy state;Dressler’s syndrome;

Drop attacks;

Drug withdrawal convulsions;

Dyspnoea;

Early infantile epileptic encephalopathy with burst-suppression;

Eclampsia;Eczema herpeticum;

Embolia cutis medicamentosa;

Embolic cerebellar infarction;

Embolic cerebral infarction;

Embolic pneumonia;

Embolic stroke;

Embolism;

Embolism arterial;

Embolism venous;

Encephalitis;

Encephalitis allergic;

Encephalitis autoimmune;

Encephalitis brain stem;

Encephalitis haemorrhagic;

Encephalitis periaxialis diffusa;

Encephalitis post immunisation;

Encephalomyelitis;

Encephalopathy;

Endocrine disorder;

Endocrine ophthalmopathy;

Endotracheal intubation;

Enteritis;Enteritis leukopenic;

Enterobacter pneumonia;

Enterocolitis;Enteropathic spondylitis;

Eosinopenia;

Eosinophilic fasciitis;

Eosinophilic granulomatosis with polyangiitis;

Eosinophilic oesophagitis;

Epidermolysis;

Epilepsy

;Epilepsy surgery;

Epilepsy with myoclonic-atonic seizures;

Epileptic aura;

Epileptic psychosis;

Erythema;

Erythema induratum;

Erythema multiforme;

Erythema nodosum;

Evans syndrome;

Exanthema subitum;

Expanded disability tatus scale score decreased;

Expanded disability status scale score increased;

Exposure to communicable disease

;Exposure to SARS-CoV-2;

Eye oedema;Eye pruritus;

Eye swelling;

Eyelid oedema;

Face oedema;

Facial paralysis;

Facial paresis;

Faciobrachial dystonic seizure;

Fat embolism;

Febrile convulsion;

Febrile infection-related epilepsy syndrome;

Febrile neutropenia;

Felty’s syndrome;

Femoral artery embolism;

Fibrillary glomerulonephritis;

Fibromyalgia;

Flushing;Foaming at mouth;

Focal cortical resection;

Focal dyscognitive seizures;

Foetal distress syndrome;

Foetal placental thrombosis;

Foetor hepaticus;

Foreign body embolism;

Frontal lobe epilepsy;

Fulminant type 1 diabetes mellitus;

Galactose elimination capacity test abnormal;

Galactose elimination capacity test decreased;

Gamma-glutamyltransferase abnormal;

Gamma-glutamyltransferase increased;

Gastritis herpes;

Gastrointestinal amyloidosis;

Gelastic seizure;

Generalised onset non-motor seizure;

Generalised tonic-clonic seizure;

Genital herpes;

Genital herpes simplex;

Genital herpes zoster;

Giant cell arteritis;

Glomerulonephritis;

Glomerulonephritis membranoproliferative;

Glomerulonephritis membranous;

Glomerulonephritis rapidly progressive;

Glossopharyngeal nerve paralysis;

Glucose transporter type 1 deficiency syndrome;

Glutamate dehydrogenase increased;

Glycocholic acid increased;

GM2 gangliosidosis;

Goodpasture’s syndrome;

Graft thrombosis;

Granulocytopenia;

Granulocytopenia neonatal;

Granulomatosis with polyangiitis;

Granulomatous dermatitis;

Grey matter heterotopia;

Guanase increased;

Guillain-Barre syndrome;

Haemolytic anaemia;

Haemophagocytic lymphohistiocytosis;

Haemorrhage;

Haemorrhagic ascites;

Haemorrhagic disorder;

Haemorrhagic pneumonia;

Haemorrhagic varicella syndrome;

Haemorrhagic vasculitis;

Hantavirus pulmonary infection;

Hashimoto’s encephalopathy;

Hashitoxicosis;

Hemimegalencephaly;

Henoch-Schonlein purpura;

Henoch-Schonlein purpura nephritis;

Hepaplastin abnormal;

Hepaplastin decreased;

Heparin-induced thrombocytopenia;

Hepatic amyloidosis;

Hepatic artery embolism;

Hepatic artery flow decreased;

Hepatic artery thrombosis;

Hepatic enzyme abnormal;

Hepatic enzyme decreased;

Hepatic enzyme increased;

Hepatic fibrosis marker abnormal;

Hepatic fibrosis marker increased;

Hepatic function abnormal;

Hepatic hydrothorax;

Hepatic hypertrophy;

Hepatic hypoperfusion;

Hepatic lymphocytic infiltration;

Hepatic mass;

Hepatic pain;

Hepatic sequestration;

Hepatic vascular resistance increased;

Hepatic vascular thrombosis;

Hepatic vein embolism;

Hepatic vein thrombosis;

Hepatic venous pressure gradient abnormal;

Hepatic venous pressure gradient increased;

Hepatitis;

Hepatobiliary scan abnormal;

Hepatomegaly;

Hepatosplenomegaly;

Hereditary angioedema with C1 esterase inhibitor deficiency;

Herpes dermatitis;

Herpes gestationis;

Herpes oesophagitis;

Herpes ophthalmic;

Herpes pharyngitis;

Herpes sepsis;

Herpes simplex;

Herpes simplex cervicitis;

Herpes simplex colitis;

Herpes simplex encephalitis

;Herpes simplex gastritis;

Herpes simplex hepatitis;

Herpes simplex meningitis;

Herpes simplex meningoencephalitis;

Herpes simplex meningomyelitis;

Herpes simplex necrotising retinopathy;

Herpes simplex oesophagitis;

Herpes simplex otitis externa;

Herpes simplex pharyngitis;

Herpes simplex pneumonia;

Herpes simplex reactivation;

Herpes simplex sepsis;

Herpes simplex viraemia;

Herpes simplex virus conjunctivitis neonatal;

Herpes simplex visceral;

Herpes virus infection;

Herpes zoster;

Herpes zoster cutaneous disseminated;

Herpes zoster infection neurological;

Herpes zoster meningitis;

Herpes zoster meningoencephalitis;

Herpes zoster meningomyelitis

Herpes zoster meningoradiculitis;

Herpes zoster necrotising retinopathy;

Herpes zoster oticus;

Herpes zoster pharyngitis;

Herpes zoster reactivation;

Herpetic radiculopathy;

Histone antibody positive;

Hoigne’s syndrome;

Human herpesvirus 6 encephalitis

Human herpesvirus 6 infection;

Human herpesvirus 6 infection reactivation;

Human herpesvirus 7 infection;

Human herpesvirus 8 infection;

Hyperammonaemia;

Hyperbilirubinaemia;

Hypercholia;ypergammaglobulinaemia benign monoclonal;

Hyperglycaemic seizure;

Hypersensitivity;

Hypersensitivity vasculitis;

Hyperthyroidism;

Hypertransaminasaemia;

Hyperventilation;Hypoalbuminaemia;

Hypocalcaemic seizure;

Hypogammaglobulinaemia;

Hypoglossal nerve paralysis;

Hypoglossal nerve paresis;

Hypoglycaemic seizure;

Hyponatraemic seizure;

Hypotension;

Hypotensive crisis;

Hypothenar hammer syndrome;

Hypothyroidism;

Hypoxia;

Idiopathic CD4 lymphocytopenia;

Idiopathic generalised epilepsy;

Idiopathic interstitial pneumonia;

Idiopathic neutropenia;

Idiopathic pulmonary fibrosis;

IgA nephropathy;

IgM nephropathy;

IIIrd nerve paralysis;

IIIrd nerve paresis;

Iliac artery embolism;

Immune thrombocytopenia;

Immune-mediated adverse reaction;

Immune-mediated cholangitis;

Immune-mediated cholestasis;

Immune-mediated cytopenia;

Immune-mediated encephalitis;

Immune-mediated encephalopathy;

Immune-mediated endocrinopathy;

Immune-mediated enterocolitis;

Immune-mediated gastritis;

Immune-mediated hepatic disorder;

Immune-mediated hepatitis;

Immune-mediated hyperthyroidism;

Immune-mediated hypothyroidism;

Immune-mediated myocarditis

;Immune-mediated myositis;

Immune-mediated nephritis;

Immune-mediated neuropathy

;Immune-mediated pancreatitis;

Immune-mediated pneumonitis;

Immune-mediated renal disorder;

Immune-mediated thyroiditis;

Immune-mediated uveitis;

Immunoglobulin G4 related disease;

Immunoglobulins abnormal;

Implant site thrombosis;

Inclusion body myositis;

Infantile genetic agranulocytosis;

Infantile spasms;

Infected vasculitis;

Infective thrombosis;

Inflammation;

Inflammatory bowel disease;

Infusion site thrombosis;

Infusion site vasculitis;

Injection site thrombosis;

Injection site urticaria;

Injection site vasculitis;

Instillation site thrombosis;

Insulin autoimmune syndrome;

Interstitial granulomatous dermatitis;

Interstitial lung disease;

Intracardiac mass;

Intracardiac thrombus;

Intracranial pressure increased;

Intrapericardial thrombosis;

Intrinsic factor antibody abnormal;

Intrinsic factor antibody positive;

IPEX syndrome;Irregular breathing;

IRVAN syndrome;

IVth nerve paralysis;

IVth nerve paresis;

JC polyomavirus test positive;

JC virus CSF test positive;

Jeavons syndrome;

Jugular vein embolism;

Jugular vein thrombosis;

Juvenile idiopathic arthritis;

Juvenile myoclonic epilepsy;

Juvenile polymyositis;

Juvenile psoriatic arthritis

;Juvenile spondyloarthritis;

Kaposi sarcoma inflammatory cytokine syndrome;

Kawasaki’s disease;

Kayser-Fleischer ring;

Keratoderma blenorrhagica;

Ketosis-prone diabetes mellitus;

Kounis syndrome;

Lafora’s myoclonic epilepsy;

Lambl’s excrescences;

Laryngeal dyspnoea;

Laryngeal oedema;

Laryngeal rheumatoid arthritis;

Laryngospasm;

Laryngotracheal oedema;

Latent autoimmune diabetes in adults;

LE cells present;

Lemierre syndrome;

Lennox-Gastaut syndrome;

Leucine aminopeptidase increased;

Leukoencephalomyelitis;

Leukoencephalopathy;

Leukopenia;

Leukopenia neonatal;

Lewis-Sumner syndrome;

Lhermitte’s sign;

Lichen planopilaris;

Lichen planus

;Lichen sclerosus;

Limbic encephalitis;

Linear IgA disease

;Lip oedema;

Lip swelling;

Liver function test abnormal;

Liver function test decreased;

Liver function test increased;

Liver induration;

Liver injury;

Liver iron concentration abnormal;

Liver iron concentration increased;

Liver opacity;

Liver palpable;

Liver sarcoidosis;

Liver scan abnormal;

Liver tenderness;

Low birth weight baby;

Lower respiratory tract herpes infection;

Lower respiratory tract infection;

Lower respiratory tract infection viral;

Lung abscess;

Lupoid hepatic cirrhosis;

Lupus cystitis;

Lupus encephalitis

;Lupus endocarditis;

Lupus enteritis;

Lupus hepatitis;

Lupus myocarditis

;Lupus myositis;

Lupus nephritis;

Lupus pancreatitis;

Lupus pleurisy;

Lupus pneumonitis;

Lupus vasculitis;

Lupus-like syndrome;

Lymphocytic hypophysitis;

Lymphocytopenia neonatal;

Lymphopenia;MAGIC syndrome;

Magnetic resonance imaging liver abnormal;

Magnetic resonance proton density fat fraction measurement;

Mahler sign;

Manufacturing laboratory analytical testing issue;

Manufacturing materials issue

;Manufacturing production issue;

Marburg’s variant multiple sclerosis;

Marchiafava-Bignami disease;

Marine Lenhart syndrome;

Mastocytic enterocolitis;

Maternal exposure during pregnancy;

Medical device site thrombosis;

Medical device site vasculitis;

MELAS syndrome;

Meningitis;

Meningitis aseptic;

Meningitis herpes;

Meningoencephalitis herpes simplex neonatal;

Meningoencephalitis herpetic;

Meningomyelitis herpes;

MERS-CoV test

;MERS-CoV test negative;

MERS-CoV test positive;

Mesangioproliferative glomerulonephritis;

Mesenteric artery embolism;

Mesenteric artery thrombosis;

Mesenteric vein thrombosis;

Metapneumovirus infection;

Metastatic cutaneous Crohn’s disease;

Metastatic pulmonary embolism;

Microangiopathy;

Microembolism;

Microscopic polyangiitis;

Middle East respiratory syndrome;

Migraine-triggered seizure;

Miliary pneumonia;

Miller Fisher syndrome;

Mitochondrial aspartate aminotransferase increased;

Mixed connective tissue disease;

Model for end stage liver disease score abnormal;

Model for end stage liver disease score increased;

Molar ratio of total branched-chain amino acid to tyrosine;

Molybdenum cofactor deficiency;

Monocytopenia;

Mononeuritis;

Mononeuropathy multiplex;

Morphoea;

Morvan syndrome;

Mouth swelling;

Moyamoya disease;

Multifocal motor neuropathy;

Multiple organ dysfunction syndrome;

Multiple sclerosis;

Multiple sclerosis relapse;

Multiple sclerosis relapse prophylaxis;

Multiple subpial transection;

Multisystem inflammatory syndrome in children;

Muscular sarcoidosis;

Myasthenia gravis;

Myasthenia gravis crisis;

Myasthenia gravis neonatal;

Myasthenic syndrome;

Myelitis;

Myelitis transverse;

Myocardial infarction;

Myocarditis;

Myocarditis post infection;

Myoclonic epilepsy;

Myoclonic epilepsy and ragged-red fibres;

Myokymia;Myositis;

Narcolepsy;

Nasal herpes;

Nasal obstruction;

Necrotising herpetic retinopathy;

Neonatal Crohn’s disease;

Neonatal epileptic seizure;

Neonatal lupus erythematosus;

Neonatal mucocutaneous herpes simplex;

Neonatal pneumonia;

Neonatal seizure;

Nephritis;

Nephrogenic systemic fibrosis;

Neuralgic amyotrophy;

Neuritis;

Neuritis cranial;

Neuromyelitis optica pseudo relapse;

Neuromyelitis optica spectrum disorder;

Neuromyotonia;

Neuronal neuropathy;

Neuropathy peripheral;

Neuropathy, ataxia, retinitis pigmentosa syndrome;

Neuropsychiatric lupus;

Neurosarcoidosis;

Neutropenia;

Neutropenia neonatal;

Neutropenic colitis;

Neutropenic infection;

Neutropenic sepsis;

Nodular rash;

Nodular vasculitis

;Noninfectious myelitis;

Noninfective encephalitis;

Noninfective encephalomyelitis;

Noninfective oophoritis;

Obstetrical pulmonary embolism;

Occupational exposure to communicable disease;

Occupational exposure to SARS-CoV-2;

Ocular hyperaemia;

Ocular myasthenia;

Ocular pemphigoid;

Ocular sarcoidosis;

Ocular vasculitis;

Oculofacial paralysis;

Oedema;Oedema bliste;r

Oedema due to hepatic disease;

Oedema mouth;

Oesophageal achalasia;

Ophthalmic artery thrombosis;

Ophthalmic herpes simplex;

Ophthalmic herpes zoster;

Ophthalmic vein thrombosis;

Optic neuritis;

Optic neuropathy;

Optic perineuritis;

Oral herpes;

Oral lichen planus;

Oropharyngeal oedema;

Oropharyngeal spasm;

Oropharyngeal swelling;

Osmotic demyelination syndrome;

Ovarian vein thrombosis;

Overlap syndrome;

Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection;

Paget-Schroetter syndrome;

Palindromic rheumatism;

Palisaded neutrophilic granulomatous dermatitis;

Palmoplantar keratoderma;

Palpable purpura;

Pancreatitis;

Panencephalitis;

Papillophlebitis;

Paracancerous pneumonia;

Paradoxical embolism;

Parainfluenzae viral laryngotracheobronchitis;

Paraneoplastic dermatomyositis;

Paraneoplastic pemphigus;

Paraneoplastic thrombosis;

Paresis cranial nerve;

Parietal cell antibody positive;

Paroxysmal nocturnal haemoglobinuria;

Partial seizures;

Partial seizures with secondary generalisation;

Patient isolation;

Pelvic venous thrombosis;emphigoid;

Pemphigus;Penile vein thrombosis;

Pericarditis;Pericarditis lupus;

Perihepatic discomfort;

Periorbital oedema;

Periorbital swelling;

Peripheral artery thrombosis;

Peripheral embolism;

Peripheral ischaemia;

Peripheral vein thrombus extension;

Periportal oedema;

Peritoneal fluid protein abnormal;

Peritoneal fluid protein decreased;

Peritoneal fluid protein increased;

Peritonitis lupus;

Pernicious anaemia;

Petit mal epilepsy;

Pharyngeal oedema;

Pharyngeal swelling;

Pityriasis lichenoides et varioliformis acuta;

Placenta praevia;

Pleuroparenchymal fibroelastosis;

Pneumobilia;

Pneumonia;

Pneumonia adenoviral;

Pneumonia cytomegaloviral;

Pneumonia herpes viral;

Pneumonia influenzal;

Pneumonia measles;

Pneumonia mycoplasmal;

Pneumonia necrotising;

Pneumonia parainfluenzae viral;

Pneumonia respiratory syncytial viral;

Pneumonia viral;

POEMS syndrome;

Polyarteritis nodosa;

Polyarthritis;

Polychondritis;

Polyglandular autoimmune syndrome type I;

Polyglandular autoimmune syndrome type II;

Polyglandular autoimmune syndrome type III;

Polyglandular disorder;

Polymicrogyria;

Polymyalgia rheumatica;

Polymyositis

;Polyneuropathy;

Polyneuropathy idiopathic progressive;

Portal pyaemia;

Portal vein embolism;

Portal vein flow decreased;

Portal vein pressure increased;

Portal vein thrombosis;

Portosplenomesenteric venous thrombosis;

Post procedural hypotension;

Post procedural pneumonia;

Post procedural pulmonary embolism;

Post stroke epilepsy;

Post stroke seizure;

Post thrombotic retinopathy;

Post thrombotic syndrome;

Post viral fatigue syndrome;

Postictal headache;

Postictal paralysis;

Postictal psychosis;

Postictal state;

Postoperative respiratory distress;

Postoperative respiratory failure;

Postoperative thrombosis;

Postpartum thrombosis;

Postpartum venous thrombosis;

Postpericardiotomy syndrome;

Post-traumatic epilepsy;

Postural orthostatic tachycardia syndrome;

Precerebral artery thrombosis;

Pre-eclampsia;

Preictal state;

Premature labour;

Premature menopause;

Primary amyloidosis;

Primary biliary cholangitis;

Primary progressive multiple sclerosis;

Procedural shock;

Proctitis herpes;

Proctitis ulcerative;

Product availability issue;

Product distribution issue;

Product supply issue;

Progressive facial hemiatrophy;

Progressive multifocal leukoencephalopathy;

Progressive multiple sclerosis;

Progressive relapsing multiple sclerosis;

Prosthetic cardiac valve thrombosis;

Pruritus;

Pruritus allergic;

Pseudovasculitis;

Psoriasis;

Psoriatic arthropathy

;Pulmonary amyloidosis;

Pulmonary artery thrombosis;

Pulmonary embolism;

Pulmonary fibrosis

;Pulmonary haemorrhage;

Pulmonary microemboli;

Pulmonary oil microembolism;

Pulmonary renal syndrome;

Pulmonary sarcoidosis;

Pulmonary sepsis;

Pulmonary thrombosis;

Pulmonary tumour thrombotic microangiopathy;

Pulmonary vasculitis;

Pulmonary veno-occlusive disease;

Pulmonary venous thrombosis;

Pyoderma gangrenosum;

Pyostomatitis vegetans;

Pyrexia;Quarantine;Radiation leukopenia;

Radiculitis brachial;

Radiologically isolated syndrome;

Rash;

Rash erythematous;

Rash pruritic;

Rasmussen encephalitis;

Raynaud’s phenomenon

;Reactive capillary endothelial proliferation;

Relapsing multiple sclerosis;

Relapsing-remitting multiple sclerosis;

Renal amyloidosis;

Renal arteritis;

Renal artery thrombosis;

Renal embolism;

Renal failure;

Renal vascular thrombosis;

Renal vasculitis;

Renal vein embolism;

Renal vein thrombosis;

Respiratory arrest;

Respiratory disorder;

Respiratory distress;

Respiratory failure;

Respiratory paralysis;

Respiratory syncytial virus bronchiolitis;

Respiratory syncytial virus bronchitis;

Retinal artery embolism;

Retinal artery occlusion;

Retinal artery thrombosis;

Retinal vascular thrombosis;

Retinal vasculitis;

Retinal vein occlusion;

Retinal vein thrombosis;

Retinol binding protein decreased;

Retinopathy;

Retrograde portal vein flow;

Retroperitoneal fibrosis;

Reversible airways obstruction;

Reynold’s syndrome;

Rheumatic brain disease;

Rheumatic disorder;

Rheumatoid arthritis;

Rheumatoid factor increased;

Rheumatoid factor positive;

Rheumatoid factor quantitative increased;

Rheumatoid lung;

Rheumatoid neutrophilic dermatosis;

Rheumatoid nodule;

Rheumatoid nodule removal;

Rheumatoid scleritis;

Rheumatoid vasculitis;

Saccadic eye movement;

SAPHO syndrome;

Sarcoidosis;

SARS-CoV-1 test;

SARS-CoV-1 test negative;

SARS-CoV-1 test positive;

SARS-CoV-2 antibody test;

SARS-CoV-2 antibody test negative;

SARS-CoV-2 antibody test positive;

SARS-CoV-2 carrier;

SARS-CoV-2 sepsis;

SARS-CoV-2 test;

SARS-CoV-2 test false negative;

SARS-CoV-2 test false positive;

SARS-CoV-2 test negative;

SARS-CoV-2 test positive;

SARS-CoV-2 viraemia;

Satoyoshi syndrome;

Schizencephaly;Scleritis;

Sclerodactylia;

Scleroderma;

Scleroderma associated digital ulcer;

Scleroderma renal crisis;

Scleroderma-like reaction;

Secondary amyloidosis;

Secondary cerebellar degeneration;

Secondary progressive multiple sclerosis;

Segmented hyalinising vasculitis;

Seizure;

Seizure anoxic;

Seizure cluster;

Seizure like phenomena;

Seizure prophylaxis;

Sensation of foreign body;

Septic embolus;

Septic pulmonary embolism;

Severe acute respiratory syndrome;

Severe myoclonic epilepsy of infancy;

Shock;

Shock symptom;

Shrinking lung syndrome;

Shunt thrombosis;

Silent thyroiditis;

Simple partial seizures;

Sjögren’s syndrome;

Skin swelling;

SLE arthritis;

Smooth muscle antibody positive;

Sneezing;

Spinal artery embolism;

Spinal artery thrombosis;

Splenic artery thrombosis;

Splenic embolism;

Splenic thrombosis;

Splenic vein thrombosis;

Spondylitis;

Spondyloarthropathy;

Spontaneous heparin-induced thrombocytopenia syndrome;

Status epilepticus;

Stevens-Johnson syndrome;

Stiff leg syndrome;

Stiff person syndrome;

Stillbirth;

Still’s disease;

Stoma site thrombosis;

Stoma site vasculitis;

Stress cardiomyopathy;

Stridor;

Subacute cutaneous lupus erythematosus;

Subacute endocarditis;

Subacute inflammatory demyelinating polyneuropathy;

Subclavian artery embolism;

Subclavian artery thrombosis;

Subclavian vein thrombosis;

Sudden unexplained death in epilepsy;

Superior sagittal sinus thrombosis;

Susac’s syndrome;

Suspected COVID-19;

Swelling;

Swelling face;

Swelling of eyelid;

Swollen tongue;

Sympathetic ophthalmia;

Systemic lupus erythematosus;

Systemic lupus erythematosus disease activity index abnormal;

Systemic lupus erythematosus disease activity index decreased;

Systemic lupus erythematosus disease activity index increased;

Systemic lupus erythematosus rash;

Systemic scleroderma;

Systemic sclerosis pulmonary;

Tachycardia;

Tachypnoea;

Takayasu’s arteritis;

Temporal lobe epilepsy;

Terminal ileitis;

Testicular autoimmunity;

Throat tightness;

Thromboangiitis obliterans;

Thrombocytopenia;

Thrombocytopenic purpura;

Thrombophlebitis;

Thrombophlebitis migrans;

Thrombophlebitis neonatal;

Thrombophlebitis septic;

Thrombophlebitis superficial;

Thromboplastin antibody positive;

Thrombosis;

Thrombosis corpora cavernosa;

Thrombosis in device;

Thrombosis mesenteric vessel;

Thrombotic cerebral infarction;

Thrombotic microangiopathy;

Thrombotic stroke;

Thrombotic thrombocytopenic purpura;

Thyroid disorder;

Thyroid stimulating immunoglobulin increased;

Thyroiditis;

Tongue amyloidosis

Tongue biting;

Tongue oedema;

Tonic clonic movements;

Tonic convulsion;

Tonic posturing;

Topectomy;

Total bile acids increased;

Toxic epidermal necrolysis;

Toxic leukoencephalopathy;

Toxic oil syndrome;

Tracheal obstruction;

Tracheal oedema;

Tracheobronchitis;

Tracheobronchitis mycoplasmal;

Tracheobronchitis viral;

Transaminases abnormal;

Transaminases increased;

Transfusion-related alloimmune neutropenia;

Transient epileptic amnesia;

Transverse sinus thrombosis;

Trigeminal nerve paresis;

Trigeminal neuralgia;

Trigeminal palsy;

Truncus coeliacus thrombosis;

Tuberous sclerosis complex;

Tubulointerstitial nephritis and uveitis syndrome;

Tumefactive multiple sclerosis;

Tumour embolism;

Tumour thrombosis;

Type 1 diabetes mellitus;

Type I hypersensitivity;

Type III immune complex mediated reaction;

Uhthoff’s phenomenon;

Ulcerative keratitis;

Ultrasound liver abnormal;

Umbilical cord thrombosis;

Uncinate fits;

Undifferentiated connective tissue disease;

Upper airway obstruction;

Urine bilirubin increased;

Urobilinogen urine decreased;

Urobilinogen urine increased;

Urticaria;

Urticaria papular;

Urticarial vasculitis;

Uterine rupture;

Uveitis;

Vaccination site thrombosis;

Vaccination site vasculitis;

Vagus nerve paralysis;

Varicella;

Varicella keratitis;

Varicella post vaccine;

Varicella zoster gastritis;

Varicella zoster oesophagitis;

Varicella zoster pneumonia;

Varicella zoster sepsis;

Varicella zoster virus infection;

Vasa praevia;Vascular graft thrombosis;

Vascular pseudoaneurysm thrombosis;

Vascular purpura;

Vascular stent thrombosis;

Vasculitic rash

;Vasculitic ulcer;

Vasculitis;

Vasculitis gastrointestinal;

Vasculitis necrotizing;

Vena cava embolism;

Vena cava thrombosis;

Venous intravasation;

Venous recanalisation;

Venous thrombosis;

Venous thrombosis in pregnancy;

Venous thrombosis limb;

Venous thrombosis neonatal;

Vertebral artery thrombosis;

Vessel puncture site thrombosis;

Visceral venous thrombosis;

VIth nerve paralysis;

VIth nerve paresis;

Vitiligo;

Vocal cord paralysis;

Vocal cord paresis;

Vogt-Koyanagi-Harada disease;

Warm type haemolytic anaemia;

Wheezing;

White nipple sign;

XIth nerve paralysis;

X-ray hepatobiliary abnormal;

Young’s syndrome;

Zika virus associated Guillain Barre syndrome

Pfizer and Moderna vaccines may create heart problems. Do not vaccinate healthy people under the age of 45.

Bad news about the dangers that mRNA vaccines may pose to the heart and blood vessels keeps coming.

A new study of 566 patients who received either the Pfizer or Moderna vaccines shows that signs of cardiovascular damage soared following the shots. The risk of heart attacks or other severe coronary problems more than doubled months after the vaccines were administered, based on changes in markers of inflammation and other cell damage.

Patients had a 1 in 4 risk for severe problems after the vaccines, compared to 1 in 9 before.

Dr. Steven Gundry, a Nebraska physician and retired cardiac surgeon, presented the findings at the Scientific Sessions of the American Heart Association’s annual conference in Boston last week. An abstract is available in Circulation, the AHA’s scientific journal.

(SOURCE: https://www.ahajournals.org/doi/abs/10.1161/circ.144.suppl_1.10712)

This is taken from the source: https://alexberenson.substack.com/p/if-you-like-heart-problems-youll

This caught my attention after having posted the conclusion from United Kingdom’s statistically valid statistics about deaths for vaccinated and unvaccinated people: https://lenbilen.com/2021/11/21/office-for-national-statistics-uk-has-some-interesting-data-on-total-death-rates-for-unvaccinated-and-vaccinated-people-below-the-age-46-you-are-better-off-without-vaccination-my-opinion/

My conclusion from that statistics is that vaccines are beneficial if you are over the age of 46. Because of the coarseness in the age-related data, only 4 categories, the uncertainity is +- 5 years. This is one more argument that speaks for the conclusion that if you are young, you are better off getting COVID-19 and acquiring natural immunity, rather than take the vaccine and be stuck with booster shots every 6 to 8 months. The vaccine itself is experimental, and we do not yet know the long term effect of it, much less the long term effect of the booster shots.

Office for National Statistics, UK has some interesting data on total death rates for unvaccinated and vaccinated people. Below the age 46 you are better off without vaccination (my opinion).

Vaccinated English adults under 60 are dying at twice the rate of unvaccinated people the same age

And have been for six months. This chart may seem unbelievable or impossible, but it’s correct, based on weekly data from the British government. The brown line represents weekly deaths from all causes of vaccinated people aged 10-59, per 100,000 people. The blue line represents weekly deaths from all causes of unvaccinated people per 100,000 in the same age range. This graph is correct. Vaccinated people under 60 are twice as likely to die as unvaccinated people. And overall deaths in Britain are running well above normal. The basic data is available here, download the Excel file and see table 4:

https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathsbyvaccinationstatusengland

This was from a news story from https://alexberenson.substack.com/p/vaccinated-english-adults-under-60

This is the first time I have seen real data from an official government agency, and I try to glean from it: At what age is the crossover point where it is advantageous to take the vaccine? At an earlier blog ( https://lenbilen.com/2021/08/02/the-delta-variant-of-the-covid-19-pandemic-is-much-less-deadly-time-to-go-back-to-normal-life/ ) I came to the conclusion that under the age of 45, unless there are special risk factors you are better off not taking the vaccine.

This new data set indicates a sharp rise in overall mortality from all cases as people get older it was given as 2 categories, unvaccinated and those having received 2 doses of vaccine, broken up in 10-60, 61-70, 71-80, and 80+ years age groups, coarse but usable categorization. This indicates a decrease in deaths of 45% for people 61-70, 46% for the age group 71-80, and 33% for people 80 and over. All these numbers jump widely so the confidence interval is only about 10%. Massaging the data as best I could with this limited set I came up with the age of 46 years as the crossover point, above which vaccines are preferable.

The conclusion is this: People over the age of 46 should be encouraged to get vaccinated, people under the age of 46 should only get vaccinated if they are in the vulnerable category, and only with a physician’s recommendation.

The case fatality rate of COVID-19 is reduced by a factor of 2.65 if HCQ + Zinc is administered as soon as possible. 1.25 Million cases are proof enough!

 

 

This picture was displayed at a Monday July 6 White House press conference. White House press secretary Kayleigh McEnany told reporters that the American death toll has fallen for weeks and the virus fatality rate is below France, the United Kingdom and Germany.

She said the death toll has significantly dropped from the height of the outbreak when the U.S. logged 2,500 deaths per day to 254 deaths on Saturday July 3, according to the article.

To confirm it the case fatality rate for Germany is as of July 15: 4.54 %

The case rate for the world is 4.24%

The corresponding number for U.S.A.: 3.83%

Is that the lowest percentage in the world?

There are more than ten countries with a lower case fatality rate. At least ten of them have one thing in common. These ten countries prescribe the use of  HydroxyChloroQuine to all people that show symptoms of COVID-19, even before a positive test is confirmed.

Turkey: 2.51%

South Korea: 2.14%

Senegal: 1.87%

Morocco: 1.58%

Russia: 1.60%

Malaysia: 1.39%

United Arab Emirates: 0.60%

Costa Rica: 0.44%

Bahrain: 0.34%

Qatar: 0.14%, but since 88% of the population are migrant workers between 20 and 60, the adjusted death rate for the permanent residents would be maybe 8 times higher, or about 1.1%

The total number of positive cases for these ten countries are over 1.2 million, far more than any double blind test could ever produce.

Taking the average, adjusted for the number of positive cases, the average adjusted death rate for ten countries, where people are taking HCQ + Zinc as soon as they are showing symptoms or diagnosed positive, is 1.60%.

This means that the risk of death is reduced by a factor of 2.65 if HZQ + Zinc is taken as early as possible after showing symptoms or after a positive diagnosis for corona-virus!

This means the daily could be reduced by 3700 a day in the world if the HCQ regimen was implemented worldwide.

For the U.S.A. the number of deaths would be reduced by an average of over 400 a day at today’s case and death rates, if HZQ + Zinc is taken as early as possible after showing symptoms or after a positive diagnosis for corona-virus!

Hydroxychloroquine + Zinc is the answer? Check the death rates of nine countries that use it.

This is a very interesting chart:

But wait. Not so fast. These countries have a younger population, and the death rate is much lower for younger people. This chart tells it all.

The death rate doubles for every 8 years as you age or about 9% per year. The world median age is 30.4 years. So let the world death rate be the norm

World death rate as of May 21 is 6.42% of diagnosed cases.

Turkey: Death rate 2.77%, median age 30.9, adjusted death rate 2.64%

South Korea: Death rate 2.37%, median age 30.9, adjusted death rate 2.26%

Malaysia: Death rate 1.61%, median age 28.5, adjusted death rate 1.91%

Senegal: Death rate 1.13%, median age 18.8, adjusted death rate 3.00%

Costa Rica: Death rate 1.11%, median age 31.3, adjusted death rate 1.02%

United Arab emirates: Death rate 0.88%, median age 30.9, adjusted death rate 0.84%

Bahrain: Death rate 1.43%, median age 32.3, adjusted death rate 1.20%

Morocco: Death rate 2.70%, median age 29.3, adjusted death rate 2.92%

Russia: Death rate 1.00%, median age 30.9, adjusted death rate 0.95%

Taking the average, not adjusted for the size of the populations we get the average adjusted death rate for countries, where people are taking HCQ + Zinc when diagnosed positive, is 1.89%.

This means that the risk of death is reduced by a factor of 3.4 if HZQ + Zinc is taken as early as possible after a positive diagnosis for coronavirus!

These 9 countries are living proof of it. Why are we not implementing it today?